AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23519225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21463065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg
Number of subjects: 16
Study 21463065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg
Number of subjects: 16
Study 21463065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17398308 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (eicosapentaenoic acid) 1800 mg daily with statin
Number of subjects: 18645
Study 17398308 — intervention group
Group type: COMPARATOR
Intervention: Statin only (control)
Number of subjects: 18645
Study 16146489 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day topiramate
Number of subjects: 470
Study 16146489 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/day topiramate
Number of subjects: 470
Study 12270591 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli presented with low probability of occurrence
Number of subjects: 0
Study 12270591 — intervention group
Group type: COMPARATOR
Intervention: Application of abstract rules in categorization
Number of subjects: 0
Study 12270591 — intervention group
Group type: EXPERIMENTAL
Intervention: No rules applied in categorization
Number of subjects: 0
Study 12270591 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus probability effect in Experiment 2
Number of subjects: 0
Study 10363865 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ardeparin 50 anti-Xa U/kg (low dose)
Number of subjects: 565
Study 10363865 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ardeparin 100 anti-Xa U/kg (high dose)
Number of subjects: 565
Study 10363865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 10363865 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including ardeparin and placebo)
Number of subjects: 565
Study 8559491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux SPAN membrane
Number of subjects: 9
Study 8559491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulphone (F60)
Number of subjects: 9
Study 8559491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux Hemophan (GFS Plus 16)
Number of subjects: 9
Study 2043015 — intervention group
Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Number of subjects: 17
Study 2043015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructosamine
Number of subjects: 17
Study 2043015 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glycated hemoglobin
Number of subjects: 17
Study 2043015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 17
Study 2043015 — intervention group
Group type: EXPERIMENTAL
Intervention: Random serum glucose
Number of subjects: 17
Study 6183631 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of foodstuffs in a double-blind trial
Number of subjects: 60
Study 6183631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge with foods that caused histamine release
Number of subjects: 60
Study 6183631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary manipulation (open-trial basis)
Number of subjects: 60
Study 6183631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of certain foodstuffs correlated to oral ulceration
Number of subjects: 60
Study 31112379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg, administered orally twice daily
Number of subjects: 576
Study 31112379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 31112379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 576
Study 29860524 — intervention group
Group type: EXPERIMENTAL
Intervention: brief cognitive behavioral therapy (bCBT)
Number of subjects: 175
Study 29860524 — intervention group
Group type: COMPARATOR
Intervention: enhanced usual care (EUC)
Number of subjects: 175
Study 26945186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg anisodamine
Number of subjects: 140
Study 26945186 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 μg anisodamine
Number of subjects: 140
Study 26945186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 μg anisodamine
Number of subjects: 140
Study 26945186 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 140
Study 24595578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Number of subjects: 0
Study 24595578 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 21943940 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 475
Study 21943940 — intervention group
Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 475
Study 18498362 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant overdenture (IOD)
Number of subjects: 36
Study 18498362 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture (CD)
Number of subjects: 36
Study 18498362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CD and IOD)
Number of subjects: 36
Study 17665604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride (anti-inflammatory drug)
Number of subjects: 24
Study 15588160 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus exercise-induced weight loss (OEWL)
Number of subjects: 24
Study 15588160 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat-induced weight loss (OWL)
Number of subjects: 24
Study 15588160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (EWL)
Number of subjects: 24
Study 12090577 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures (2-0 Dexon II)
Number of subjects: 162
Study 12090577 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable sutures (2-0 Prolene)
Number of subjects: 162
Study 10460526 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled propofol
Number of subjects: 61
Study 10460526 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 61
Study 7598067 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (increased average calcium intake by 17.9 mmol/d or 714 mg/d)
Number of subjects: 60
Study 7598067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unsupplemented)
Number of subjects: 60
Study 2221586 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 mg/kg)
Number of subjects: 6
Study 2221586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study 29347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g single dose
Number of subjects: 0
Study 29347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation (Citro‐Soda; Abbott) 12 g single dose
Number of subjects: 0
Study 29347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate preparation (Citro‐Soda; Abbott) 4 g and 12 g doses after 3-6 days of continuous therapy every 6 hours
Number of subjects: 0
Study 30826255 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping the Body in Mind Xtend pilot lifestyle program
Number of subjects: 0
Study 29381788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group (n = 21) received a behavioral consultation session targeting sleep hygiene
Number of subjects: 42
Study 29381788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group (n = 21)
Number of subjects: 42
Study 29381788 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 42
Study 27447966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 5, day 2) plus Paclitaxel (175 mg/m2, day 1)
Number of subjects: 91
Study 27447966 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin (75 mg/m2, day 1) plus Paclitaxel (175 mg/m2, day 2)
Number of subjects: 91
Study 23703878 — intervention group
Group type: COMPARATOR
Intervention: Surgical cutdown (C)
Number of subjects: 30
Study 23703878 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous access (P)
Number of subjects: 30
Study 23296282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-energetic diet (-600 kcal/day)
Number of subjects: 771
Study 23296282 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 771
Study 21121410 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 2 mg + bromhexine HCI 8 mg + guaiphenesin 100 mg (group A)
Number of subjects: 426
Study 21121410 — intervention group
Group type: COMPARATOR
Intervention: salbutamol 2 mg + guaiphenesin 100 mg (group B)
Number of subjects: 426
Study 21121410 — intervention group
Group type: COMPARATOR
Intervention: salbutamol 2 mg + bromhexine 8 mg (group C)
Number of subjects: 426
Study 17951945 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (2 gm pearls per day, given in two equal doses)
Number of subjects: 33
Study 17951945 — intervention group
Group type: COMPARATOR
Intervention: Control (no Omega-3 supplementation)
Number of subjects: 33
Study 16208150 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide
Number of subjects: 556
Study 16208150 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 556
Study 12118962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-piperacillin
Number of subjects: 471
Study 12118962 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin-piperacillin
Number of subjects: 471
Study 10396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned outpatient follow up 6‐12 weeks after surgery
Number of subjects: 264
Study 10396473 — intervention group
Group type: COMPARATOR
Intervention: No planned follow up
Number of subjects: 264
Study 7594073 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide angiography
Number of subjects: 73
Study 7594073 — intervention group
Group type: COMPARATOR
Intervention: X-ray angiography
Number of subjects: 73
Study 2273081 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.25 mg)
Number of subjects: 8
Study 2273081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7247286 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 534
Study 7247286 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 534
Study 28802772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training and home-based walking programme
Number of subjects: 52
Study 28802772 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 52
Study 27719707 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide group
Number of subjects: 20
Study 27719707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined triamcinolone acetonide and salvia miltiorrhiza group
Number of subjects: 20
Study 27719707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 27719707 — intervention group
Group type: EXPERIMENTAL
Intervention: OSF group
Number of subjects: 20
Study 24392848 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (100 μg twice daily)
Number of subjects: 362
Study 24392848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 22894553 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg per day)
Number of subjects: 1199
Study 22894553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 20147581 — intervention group
Group type: EXPERIMENTAL
Intervention: NOF guidelines
Number of subjects: 1471
Study 20147581 — intervention group
Group type: EXPERIMENTAL
Intervention: NOGG guidelines
Number of subjects: 1471
Study 18484588 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 351
Study 18484588 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting for results of the CT scan
Number of subjects: 351
Study 15733046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization-enhanced exercise
Number of subjects: 55
Study 15733046 — intervention group
Group type: COMPARATOR
Intervention: General exercise only
Number of subjects: 55
Study 12517686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) infusion
Number of subjects: 21
Study 10648307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NIC) 30 microg/kg
Number of subjects: 132
Study 10648307 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (ESM) 1.0 mg/kg
Number of subjects: 132
Study 10648307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (COMB) of NIC and ESM (one-half dose each)
Number of subjects: 132
Study 10648307 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT) with no pretreatment
Number of subjects: 132
Study 8646474 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 31
Study 8646474 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 31
Study 1644543 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-open hemorrhoidectomy (group A)
Number of subjects: 300
Study 1644543 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (group B)
Number of subjects: 300
Study 6496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight men (fed state)
Number of subjects: 12
Study 6496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men (fed state)
Number of subjects: 12
Study 6496394 — intervention group
Group type: COMPARATOR
Intervention: Normal weight men (fasting state)
Number of subjects: 12
Study 6496394 — intervention group
Group type: COMPARATOR
Intervention: Obese men (fasting state)
Number of subjects: 12
Study 30680963 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy after surgical resection
Number of subjects: 162
Study 30680963 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 162
Study 30367804 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritist 'passe' (SP) sessions for 3 days
Number of subjects: 25
Study 30367804 — intervention group
Group type: COMPARATOR
Intervention: Sham sessions for 3 days
Number of subjects: 25
Study 26244591 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure (APA)
Number of subjects: 61
Study 26244591 — intervention group
Group type: COMPARATOR
Intervention: Sham-Auricular Point Acupressure (sham-APA)
Number of subjects: 61
Study 25199121 — intervention group
Group type: EXPERIMENTAL
Intervention: 6° head-down tilted bed rest (HDT) for 21 days
Number of subjects: 7
Study 22244636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency maintained (PS and PB)
Number of subjects: 71
Study 22244636 — intervention group
Group type: COMPARATOR
Intervention: No patency (NPS and NPB)
Number of subjects: 71
Study 22244636 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency maintained in big canals (PB)
Number of subjects: 71
Study 19935757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry tablets
Number of subjects: 5
Study 19935757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 5
Study 19935757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract tablets
Number of subjects: 5
Study 19935757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 17325642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 44
Study 17325642 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting (relaxation)
Number of subjects: 44
Study 16286672 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/KIC (3 g HMB and 0.3 g alpha-ketoisocaproic acid, daily)
Number of subjects: 6
Study 16286672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12000379 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP850 (20 mg kg-1 intravenously as a single dose)
Number of subjects: 13
Study 12000379 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 13
Study 12000379 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP850
Number of subjects: 13
Study 9865985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime 200 mg combined with probenecid 500 mg three times daily for 100 days
Number of subjects: 60
Study 9865985 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 2 g daily for 14 days followed by oral amoxicillin 500 mg combined with probenecid 500 mg three times daily for 100 days
Number of subjects: 60
Study 7869937 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 32
Study 7869937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 32
Study 2803397 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin (n = 14)
Number of subjects: 49
Study 2803397 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin (n = 10)
Number of subjects: 49
Study 2803397 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine (n = 14)
Number of subjects: 49
Study 2803397 — intervention group
Group type: COMPARATOR
Intervention: Group 4: Retroauricular infiltration anaesthesia with prilocaine and epinephrine (n = 14)
Number of subjects: 49
Study 809253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TRH
Number of subjects: 0
Study 809253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TRH
Number of subjects: 0
Study 30961412 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (TSST)
Number of subjects: 32
Study 30961412 — intervention group
Group type: COMPARATOR
Intervention: Control condition (P-TSST)
Number of subjects: 32
Study 27826874 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day aprepitant regimen on top of ondansetron plus dexamethasone
Number of subjects: 494
Study 27826874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control regimen) on top of ondansetron plus dexamethasone
Number of subjects: 494
Study 25307195 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-led lifestyle behavior intervention (group education and individual coaching)
Number of subjects: 223
Study 25307195 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-led lifestyle behavior intervention
Number of subjects: 223
Study 25307195 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparable length educational program)
Number of subjects: 223
Study 22617866 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Neurofeedback (NF)
Number of subjects: 39
Study 22617866 — intervention group
Group type: COMPARATOR
Intervention: Sham Neurofeedback (sham-NF)
Number of subjects: 39
Study 17034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sebum output level
Number of subjects: 60
Study 17034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 60
Study 17034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation phase
Number of subjects: 60
Study 17034515 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of acne
Number of subjects: 60
Study 12884360 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered lipid diets (fish oil supplement or seafood diet)
Number of subjects: 25
Study 12884360 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered lipid diets (Lorenzo's oil diet)
Number of subjects: 25
Study 12884360 — intervention group
Group type: COMPARATOR
Intervention: Normal lipid composition
Number of subjects: 25
Study 10833208 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg intramuscularly once weekly for 40 weeks
Number of subjects: 76
Study 10833208 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 40 weeks
Number of subjects: 76
Study 10833208 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg intramuscularly once weekly
Number of subjects: 76
Study 10833208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 8799522 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of rigidity measured by torque required to move the forearm
Number of subjects: 20
Study 8799522 — intervention group
Group type: EXPERIMENTAL
Intervention: Work required under activation
Number of subjects: 20
Study 8799522 — intervention group
Group type: COMPARATOR
Intervention: Work ratio in spouses of parkinsonians
Number of subjects: 20
Study 8799522 — intervention group
Group type: COMPARATOR
Intervention: Sinemet CR (levodopa 200 mg/carbidopa 50 mg)
Number of subjects: 20
Study 8799522 — intervention group
Group type: COMPARATOR
Intervention: Sinemet-Plus (levodopa 100 mg/carbidopa 25 mg)
Number of subjects: 20
Study 8799522 — intervention group
Group type: COMPARATOR
Intervention: Benzhexol (2 mg tablets)
Number of subjects: 20
Study 1483496 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famotidine (40 mg)
Number of subjects: 16
Study 1483496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (20 mg)
Number of subjects: 16
Study 6397847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 213
Study 6397847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 31037285 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg intravitreous injection every 4 weeks)
Number of subjects: 702
Study 31037285 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 702
Study 31037285 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 702
Study 31037285 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept vs Laser photocoagulation
Number of subjects: 702
Study 31037285 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept vs Observation
Number of subjects: 702
Study 31037285 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation vs Observation
Number of subjects: 702
Study 31037285 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 702
Study 27977439 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sternal infusion of 0.2% ropivacaine (3 ml/h through each catheter)
Number of subjects: 120
Study 27977439 — intervention group
Group type: COMPARATOR
Intervention: Standardised care only
Number of subjects: 120